Holothuria Leucospilota polysaccharides alleviate hyperlipidemia via alteration of lipid metabolism and inflammation‐related gene expression

Hyperlipemia is becoming a chronic disease that threatens human health. At the same time, people pay more and more attention to hyperlipemia. Holothuria Leucospilota polysaccharide (HLP) has been reported to ameliorate hyperlipidemia in high-fat diet-induced rats. Therefore, this study aimed to explore further metabolomics' role in improving liver function and reveal its mechanism. After oral administration of HLP for 4 weeks, total cholesterol (TC) and triglycerides (TG) levels of the liver in 100 and 200 mg/kg HLP groups were both decreased significantly (p < .05). The results showed that serum AST and ALT activity decreased by professing to be convinced of HLP. HLP also exerted antioxidant activities and up-regulated the expression of ACC, CD36, TNF-α and NF-κB in the liver of diabetic rats. Six potential biomarkers were recognized by UPLC-Q-TOF/MS and OPLS-DA. HLP alleviated liver injury by regulating the contents of metabolic end products in the serum of hyperlipidemic rats, such as nadolol and glycodeoxycholic acid. The results indicated that HLP effectively relieved HFD-induced hyperlipidemia by regulating metabolic disorders. PRACTICAL APPLICATIONS: As a chronic disease, hyperlipidemia has attracted more and more attention. Studies have shown that HLP regulates dyslipidemia, oxidative damage and inflammation to relieve hyperlipidemia. It mainly improved the liver damage caused by hyperlipidemia by inhibiting the expression of hepatic lipogenesis, oxidative stress and inflammatory factors. At the same time, we also detected six metabolites, among which high GDCA content indicated serious liver damage. Therefore, in the future, it can be suggested that HLP may be used as a functional, active substance in health products to assist in relieving hyperlipidemia, and GDCA may be used as an essential metabolic marker for the degree of liver injury.